These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38995268)

  • 1. Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
    Choi Y; Dharia NV; Jun T; Chang J; Royer-Joo S; Yau KK; Assaf ZJ; Aimi J; Sivakumar S; Montesion M; Sacher A; LoRusso P; Desai J; Schutzman JL; Shi Z;
    Clin Cancer Res; 2024 Sep; 30(17):3788-3797. PubMed ID: 38995268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS
    Ernst SM; van Marion R; Atmodimedjo PN; de Jonge E; Mathijssen RHJ; Paats MS; de Bruijn P; Koolen SL; von der Thüsen JH; Aerts JGJV; van Schaik RHN; Dubbink HJ; Dingemans AC
    J Thorac Oncol; 2024 Jul; 19(7):995-1006. PubMed ID: 38615940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a
    Sacher A; LoRusso P; Patel MR; Miller WH; Garralda E; Forster MD; Santoro A; Falcon A; Kim TW; Paz-Ares L; Bowyer S; de Miguel M; Han SW; Krebs MG; Lee JS; Cheng ML; Arbour K; Massarelli E; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Dharia NV; Schutzman JL; Desai J;
    N Engl J Med; 2023 Aug; 389(8):710-721. PubMed ID: 37611121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
    Paweletz CP; Heavey GA; Kuang Y; Durlacher E; Kheoh T; Chao RC; Spira AI; Leventakos K; Johnson ML; Ou SI; Riely GJ; Anderes K; Yang W; Christensen JG; Jänne PA
    Clin Cancer Res; 2023 Aug; 29(16):3074-3080. PubMed ID: 37279096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
    Desai J; Alonso G; Kim SH; Cervantes A; Karasic T; Medina L; Shacham-Shmueli E; Cosman R; Falcon A; Gort E; Guren T; Massarelli E; Miller WH; Paz-Ares L; Prenen H; Amatu A; Cremolini C; Kim TW; Moreno V; Ou SI; Passardi A; Sacher A; Santoro A; Stec R; Ulahannan S; Arbour K; Lorusso P; Luo J; Patel MR; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Jun T; Dharia NV; Schutzman JL; ; Han SW
    Nat Med; 2024 Jan; 30(1):271-278. PubMed ID: 38052910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
    Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
    J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of
    Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
    JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting.
    Mardinian K; Okamura R; Kato S; Kurzrock R
    Int J Cancer; 2020 Jan; 146(2):566-576. PubMed ID: 31199507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adagrasib in Advanced Solid Tumors Harboring a
    Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
    J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.